MDWD - MediWound inks distribution pact for NexoBrid in UAE

MediWound (MDWD) has further expanded its NexoBrid presence and entered the Middle Eastern markets with the signing of a distribution agreement granting Ghassan Aboud, having exclusive right to market and distribute NexoBrid in UAE for the treatment of severe burns. Commercialization of NexoBrid in the UAE will commence upon securing regulatory approval, which is expected within a year.NexoBrid (concentrate of proteolytic enzymes enriched in Bromelain) removes nonviable burn tissue, in patients with thermal burns within four hours of application without harming viable tissue.

For further details see:

MediWound inks distribution pact for NexoBrid in UAE